Baxter International Inc.

Release Summary

Baxter today announced pivotal Phase I/III study results evaluating the safety and efficacy of BAX 326, an investigational recombinant factor IX (rFIX) protein, during the ASH 54th Annual Meeting.

Baxter International Inc.